Recent Updates — NAMSW
On September 29, 2026, NewAmsterdam Pharma Company N.V. announced the dosing of the first patient in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in individuals with preclinical Alzheimer’s disease. The study will assess changes in blood-based biomarkers associated with Alzheimer's pathology, including p-tau 217, as well as cognitive and functional measures in approximately 400 participants over 52 weeks. This development expands the company's clinical program for obicetrapib alongside ongoing Phase 3 trials for cardiovascular indications. NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company developing oral, non-statin medicines to lower LDL cholesterol and treat cardiometabolic and neurodegenerative diseases.
NewAmsterdam Pharma Co. and partner Menarini Group announced that the European Commission granted marketing authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) across EU Member States, Iceland, Liechtenstein, and Norway. This marks the first global regulatory approval for obicetrapib. The Company is entitled to tiered double-digit percentage royalties on net sales in the Menarini Territory and up to an additional €833 million in clinical, regulatory, and commercial milestones. Milestone payments in the mid-teens of millions of euros are triggered by these specific marketing authorizations. NewAmsterdam Pharma Co. operates in the biopharmaceutical industry, developing therapies for cardiovascular disease.
NewAmsterdam Pharma Co. disclosed that Chief Operating Officer Douglas Kling resigned effective August 14, 2026, to become CEO of another clinical-stage biotech company. Unvested stock options and restricted stock units were canceled, except for those eligible to vest through May 14, 2027 contingent on his advisory services. Mr. Kling entered an Advisor Agreement providing transition support for the PREVAIL clinical trial of obicetrapib in exchange for a $50,000 monthly fee plus expenses until May 14, 2027. The company operates as a clinical-stage biopharmaceutical firm focused on developing treatments for metabolic and cardiovascular diseases.
NewAmsterdam Pharma Company N.V. reported financial results for the quarter ended June 30, 2026, announcing a net loss of $64.1 million and revenue of $3.7 million. The company holds $678.3 million in cash, cash equivalents, and marketable securities. Clinically, NewAmsterdam received a positive CHMP opinion from the European Medicines Agency recommending marketing authorization for obicetrapib and its combination with ezetimibe for treating primary hypercholesterolemia or mixed dyslipidemia. The firm plans to announce an interim analysis of its Phase 3 PREVAIL cardiovascular outcomes trial in the fourth quarter of 2026, with results expected in the first quarter of 2027. Additionally, topline data from the Phase 3 RUBENS trial is anticipated by year-end 2026. NewAmsterdam Pharma Company N.V. operates as a late-stage biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C.
Douglas Kling notified NewAmsterdam Pharma Company N.V. of his resignation as Chief Operating Officer, effective August 14, 2026, to become CEO of another clinical-stage biotech firm. The company expects to enter into a separation agreement and an advisor agreement with Mr. Kling to provide transition and advisory services regarding the PREVAIL clinical trial of obicetrapib and other clinical programs. Material terms of these agreements will be disclosed in a future amendment. NewAmsterdam Pharma is a clinical-stage biotechnology company.